Shire at sector perform by RBC

RBC Capital Markets analyst Douglas Miehm rated Shire Pharmaceuticals at sector perform, above average risk, with a $57 price target after the company reported third-quarter earnings per share of $0.40, up from $0.38 in the prior-year period. Results were ahead of Miehm's estimate of $0.36 and consensus forecast of $0.34. Shire's revenue of was up 19% from the previous year at $449.4 million and in line with expectations. Miehm noted that Adderall XR and Fosrenol revenues were slightly weaker than expected. Shares of the Basingstoke, England-based pharmaceutical company were down 53 cents, or 1.17%, at $53.41. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.